IP Library Granted Patent US 12697403
Granted Patent B2
US 12697403 · App. 17/576,569 · Granted Aug 4, 2026

Small molecules for dual function positron emission tomography (PET) and cell suicide switches

Inventors: Michael Farwell (Wynnewood, PA); Mark Sellmyer (Philadelphia, PA); Katheryn M. Lohith (Lansdale, PA)
Assignee: The Trustees of the University of Pennsylvania
A61K51/0459A61K31/506A61K38/1774A61K40/11A61K40/31A61K40/42A61K51/0463C12N9/003C12N9/22C12N15/85C12Y105/01003G01N33/505A61K2239/25C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697403
App. No.
17/576,569
Granted
Aug 4, 2026
Kind
B2
Abstract

The present invention includes an engineered cell comprising a chimeric antigen receptor (CAR) further comprising a nucleic acid molecule comprising a suicide gene comprising a ligand binding domain and a suicide domain wherein the ligand binding domain is capable of binding to radiolabeled tracer or a small molecule suicide switch. This invention also includes methods for inducing apoptosis of an engineered cell, methods for assessing the efficacy or toxicity of an adoptive cell therapy in a subject, methods for detecting the quantity of engineered T cells in a subject, methods for monitoring an immunotherapy treatment in a subject and methods of imaging engineered T cells in a subject. In some embodiments, the imaging is performed via Positron Emission Topography (PET). This invention further includes a chemical inducer of dimerization (CID), wherein the CID is a Bis-Trimethoprim (Bis-TMP).

Claims (2)

1 . An engineered cell comprising a chimeric antigen receptor (CAR) and further comprising a nucleic acid molecule comprising a suicide gene encoding a fusion protein comprising an E. coli dihydrofolate reductase (eDHFR) ligand binding domain and a suicide domain comprising an inducible caspase 9 (iCasp9) domain, wherein the fusion protein further comprises a linker consisting of 15 or 18 amino acids in length.

2 . The engineered cell of claim 1 , wherein the cell is a T cell.